Tyme Technologies, Inc. TYME
We take great care to ensure that the data presented and summarized in this overview for TYME TECHNOLOGIES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TYME
Top Purchases
Top Sells
About TYME
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.
Insider Transactions at TYME
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2022
|
Timothy Tyson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,865
-100.0%
|
-
|
|
Sep 16
2022
|
Gerald H Sokol Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,865
-100.0%
|
-
|
|
Sep 16
2022
|
Frank L. Porfido Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 16
2022
|
Douglas A Michels Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
110,000
-100.0%
|
-
|
|
Sep 16
2022
|
Steve Hoffman Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,022,566
-100.0%
|
-
|
|
Sep 16
2022
|
Barbara Galaini Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
258,300
-100.0%
|
-
|
|
Sep 16
2022
|
David Carberry Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
100,000
-100.0%
|
-
|
|
Sep 16
2022
|
James Biehl Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
150
-100.0%
|
-
|
|
Sep 16
2022
|
James Biehl Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
105,000
-100.0%
|
-
|
|
Sep 07
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
80,000
-0.36%
|
$0
$0.24 P/Share
|
|
Sep 06
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
80,000
-0.35%
|
$0
$0.26 P/Share
|
|
Aug 23
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
80,000
-0.35%
|
$0
$0.29 P/Share
|
|
Aug 22
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
80,000
-0.35%
|
$0
$0.29 P/Share
|
|
Jul 26
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,000
-0.31%
|
$0
$0.29 P/Share
|
|
Jul 25
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,000
-0.31%
|
$0
$0.29 P/Share
|
|
Jul 12
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,000
-0.3%
|
$0
$0.29 P/Share
|
|
Jul 11
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,000
-0.3%
|
$0
$0.29 P/Share
|
|
Jun 28
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,000
-0.26%
|
$0
$0.27 P/Share
|
|
Jun 27
2022
|
Michael Demurjian > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,000
-0.26%
|
$0
$0.26 P/Share
|
|
Jun 22
2022
|
Steve Hoffman Director |
SELL
Open market or private sale
|
Direct |
78,125
-0.39%
|
$0
$0.27 P/Share
|